Ectopic Pregnancy
Conditions
Keywords
LETREZOLE, Ectopic pregnancy, Induced abortion
Brief summary
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.
Detailed description
Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects.
Interventions
PROCEDURElaparoscopic salpingectomy
laparoscopic salpingectomy
GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
Sponsors
Zagazig University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed ectopic pregnancy was by * Absence of an intrauterine gestational sac on vaginal ultrasound Coupled with * β-hCG titers beyond the discrimination zone of at least 2,000 milli-International units (mIU/m).
Exclusion criteria
* Patients had contraindications for letrozole * Patients with any systemic disease ( diabetes, hypertension, ....) * Patients with b-hCG levels \>3,000 mIU/mL * Patients with hemoglobin level \<10 g/dL, * Patients with platelets count \<150,000/mL, * Patients with elevated liver enzymes, * Patients with elevated blood urea, or serum creatinine * The presence of a fetal heartbeat in a gestational sac detected outside the uterine cavity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| β-hCG level | The β-hCG levels were assessed on the 1st of treatment | A quantitative human chorionic gonadotropin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete blood count (CBC) | Assessed on the 1st day of treatment | Complete blood count |
| Alanine Amino Transferase (ALT) | Assessed on the 1st and 11th day of treatment | Liver enzyme |
| Aspartate aminotransferase (AST) | Assessed on the 1st and 11th day of treatment | Liver enzyme |
| Serum creatinine | Assessed on the 1st and 11th day of treatment | Renal function test |
| Blood urea | Assessed on the 1st and 11th day of treatment | Renal function test |
Countries
Egypt
Outcome results
None listed